Brookline Capital Acquisition Forecasts NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at Brookline Capital Acquisition cut their FY2026 earnings estimates for shares of Intellia Therapeutics in a note issued to investors on Thursday, February 26th. Brookline Capital Acquisition analyst L. Cann now anticipates that the company will earn ($3.11) per share for the year, down from their prior estimate of ($2.13). Brookline Capital Acquisition currently has a “Buy” rating on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Brookline Capital Acquisition also issued estimates for Intellia Therapeutics’ FY2027 earnings at $15.05 EPS and FY2030 earnings at $78.43 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. During the same period last year, the company posted ($1.27) earnings per share. The business’s revenue for the quarter was up 78.4% on a year-over-year basis.

A number of other equities research analysts have also recently issued reports on NTLA. JonesTrading cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Evercore set a $8.00 target price on shares of Intellia Therapeutics and gave the company an “in-line” rating in a research note on Tuesday, November 11th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 18th. Bank of America reissued a “neutral” rating on shares of Intellia Therapeutics in a research report on Monday. Finally, William Blair upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday. Ten analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Hold” and an average target price of $19.14.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.60 on Monday. The company has a market capitalization of $1.61 billion, a P/E ratio of -3.55 and a beta of 2.10. The stock’s 50 day moving average price is $12.09 and its 200 day moving average price is $13.10. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Headlands Technologies LLC bought a new stake in Intellia Therapeutics during the second quarter worth about $26,000. Comerica Bank raised its stake in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the last quarter. Blue Bell Private Wealth Management LLC acquired a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd bought a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Finally, Advisory Services Network LLC bought a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $33,000. Institutional investors own 88.77% of the company’s stock.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.